Fol­low­ing Syn­tim­mune buy­out, Alex­ion antes up $25M to dou­ble down on an­ti-FcRn path­way

Last Sep­tem­ber, Alex­ion wa­gered $1.2 bil­lion — $400 mil­lion of it up­front — on lit­tle biotech Syn­tim­mune to get its hands on a drug tar­get­ing IgG …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.